A live webcast will be available in the investor section of the company’s website at www.vervetx.com. The webcast will be archived for 30 days following the presentation.

Investor Contact Jen Robinson Verve Therapeutics, Inc. [email protected] Media Contact Ashlea Kosikowski Das Börsenjahr 2025 klopft schon an die Tür – und wie immer geht es um die Frage ...

BOSTON, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today highlighted its recent pipeline ...

BOSTON, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on December 31 ...

Residents and businesses in Alphen Park and Ashlea Gardens, east of Pretoria are still plunged in the dark with no estimation of when electricity will be restored after a power outage that ...

Initial data for the Heart-2 Phase 1b clinical trial of VERVE-102 targeting PCSK9 expected in second quarter of 2025 Dosing in the Heart-2 trial has moved to the 0.6 mg/kg cohort VERVE-301 ...

BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that Sekar Kathiresan ...

Initial data for the Heart-2 Phase 1b clinical trial of VERVE-102 targeting PCSK9 expected in second quarter of 2025 Dosing in the Heart-2 trial has moved to the 0.6 mg/kg cohort VERVE-301 nominated ...

(MENAFN- GlobeNewsWire - Nasdaq) BOSTON, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics , a clinical-stage company developing a new class of genetic medicines for cardiovascular disease ...